CMV and HHV6 Reactivation in CAR T Cells

The risk factors were identified to be low NC at day 30, grade 2 or higher CRS or icons and a high cumulative steroid dose during the first 30 days after CAR T cell infusion. There was another study presented in the tandem conference back this February by the Fred Hodge group, they actually enrolled 36 CMV seropositive adult CAR T cell recipients. About 20% of these patients had a CMV reactivation and about 10% had a HHV6 reactivation. Of those seven patients who were CMV activation only two received preemptive therapy; there were no cases of end-organ disease for either CMV or HHV6.